Inhibrx Biosciences expands Oxford Finance loan facility to USD 500 millionPUBT·Jul 16 at 08:04 AMINBX-4.00%
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & Morerttnews·Jun 24 at 09:09 AMINBX-4.00%PVLA+3.55%
Inhibrx Biosciences's BLA Filing For Ozekibart Gets FDA Acceptancerttnews·Jun 15 at 08:35 AMINBX-4.00%
Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)Tip Ranks·May 15 at 07:45 AMINBX-4.00%PBE+0.64%
Inhibrx Reports First Quarter 2026 Financial Results | INBX Stock NewsStockTitan·May 14 at 07:02 AMINBX-4.00%PBE+0.64%
Inhibrx announces positive interim results from HexAgon trialWorldPharmaceuticals·May 12 at 03:42 AMINBX-4.00%BIB0.00%
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer StudyMarket Beat·May 11 at 11:08 AMINBX-4.00%MRK+2.66%
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy | INBX Stock NewsStockTitan·May 10 at 11:00 PMINBX-4.00%BBH+2.79%
